You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 14, 2025

Details for New Drug Application (NDA): 217225

✉ Email this page to a colleague

NDA 217225 describes IZERVAY, which is a drug marketed by Astellas and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug. Additional details are available on the IZERVAY profile page.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this compound. Additional details are available on the avacincaptad pegol sodium profile page.

Summary for 217225

Tradename:	IZERVAY
Applicant:	Astellas
Ingredient:	avacincaptad pegol sodium
Patents:	9

Pharmacology for NDA: 217225

Mechanism of Action	Complement Inhibitors

Suppliers and Packaging for NDA: 217225

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
IZERVAY	avacincaptad pegol sodium	SOLUTION;INTRAVITREAL	217225	NDA	Astellas Pharma US, Inc.	82829-002	82829-002-01	1 VIAL, SINGLE-DOSE in 1 CARTON (82829-002-01) / .35 mL in 1 VIAL, SINGLE-DOSE
IZERVAY	avacincaptad pegol sodium	SOLUTION;INTRAVITREAL	217225	NDA	Astellas Pharma US, Inc.	82829-002	82829-002-99	1 VIAL, SINGLE-DOSE in 1 CARTON (82829-002-99) / .35 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INTRAVITREAL			Strength	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)
Approval Date:	Aug 4, 2023	TE:		RLD:	Yes
Patent:	⤷ Get Started Free	Patent Expiration:	Feb 14, 2025	Product Flag?		Substance Flag?	Y	Delist Request?
Patented Use:	TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Patent:	⤷ Get Started Free	Patent Expiration:	Jul 11, 2034	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE
Patent:	⤷ Get Started Free	Patent Expiration:	Jul 11, 2034	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE

Expired US Patents for NDA 217225

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astellas	IZERVAY	avacincaptad pegol sodium	SOLUTION;INTRAVITREAL	217225-001	Aug 4, 2023	⤷ Get Started Free	⤷ Get Started Free
Astellas	IZERVAY	avacincaptad pegol sodium	SOLUTION;INTRAVITREAL	217225-001	Aug 4, 2023	⤷ Get Started Free	⤷ Get Started Free
Astellas	IZERVAY	avacincaptad pegol sodium	SOLUTION;INTRAVITREAL	217225-001	Aug 4, 2023	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.